Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Brazil / NCT07036302
Active, not recruiting Not applicable

Comparative Effects Of Trichloroacetic Chemical Peel And Fractional Laser

NCT07036302 · tracked via the Priya Life Science Brazil tracker
Sponsor
Jose Roberto Cortelli
Phase
Not applicable
Started
2025-06-02
Last updated
2026-05-19

Condition(s) studied

MelasmaAcne Scars - Mixed Atrophic and HypertrophicResurfacingRejuvenation

Investigational drug(s) / intervention(s)

35% TCA combined with croton oil peelIsolate 35% TCA peelErbium-YAG laserNeodymium -YAG laser Q-switched

35% TCA combined with croton oil peel: 3 sections every 30 days of 35% TCA combined with croton oil peel

Isolate 35% TCA peel: 3 sections every 30 days of isolate 35% TCA peel

Erbium-YAG laser: 3 sections every 30 days of Er-YAG laser

Neodymium -YAG laser Q-switched: 3 sections every 30 days of ND-YAG laser

Study summary

More than aesthetics, the search for orofacial harmonization treatments has increased when the negative emotional impact of some facial conditions such as melasma and acne scars is recognized. This study will evaluate the effects of chemical peels with 35% TCA (trichloroacetic acid) and two types of fractional laser in orofacial harmonization procedures. A sample of 100-120 participants at least 18 years of age, male or female, with complaints of melasma (n=36 to 40), acne scars (n=36 to 40) or facial wrinkles (n=36 to 40) will be recruited to underwent 3 consecutive treatment sections every 30 days. Besides clinical improvements, global satisfaction scale of the professional and the patient will be measured in addition to the impact of the treatment on the quality of life of the participants and the sensory experience in relation to pain. Pre- and pos-peeling home care will be provided to measure whether they influence results or not. The aim of this study is to identify the most appropriate treatment strategy for frequent complaints in clinical practice, and among them, the one that promotes the best experience, with the shortest recovery time and is cost-effective.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Men or women * aged 18 or over * acne scars, melasma or clear signs of photoaging and evident wrinkles * participants with acne scars or melasma will be included if they have never undergone treatment or if previous treatment has been ineffective. Exclusion Criteria: * phototype VI * autoimmune and dermatological diseases * known allergies to the components of the formulations * patients who prefer other treatment options * history of keloids * pregnant women * breastfeeding women * women of childbearing age who do not adopt a valid method of contraception

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Cavalca & Cortelli Research Center Taubaté São Paulo
University of Taubate Dental School Taubaté São Paulo

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07036302 on ClinicalTrials.gov ↗ ← All trials in Brazil